NASDAQ:BOLT

Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis

Bolt Biotherapeutics logo
$5.80 -0.28 (-4.61%)
Closing price 04:00 PM Eastern
Extended Trading
$5.83 +0.03 (+0.52%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bolt Biotherapeutics Stock (NASDAQ:BOLT)

Advanced

Key Stats

Today's Range
$5.61
▼
$6.05
50-Day Range
$3.35
▼
$6.59
52-Week Range
$3.10
▼
$7.78
Volume
115,705 shs
Average Volume
92,575 shs
Market Capitalization
$11.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.50
Consensus Rating
Hold

Company Overview

Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer.

The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors.

Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate. The company’s programs are in clinical development, and its therapies are not established treatments for cancer.

AI Generated. May Contain Errors.

Bolt Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

BOLT MarketRank™: 
3.704931071045 of 5 stars

Bolt Biotherapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 158th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Bolt Biotherapeutics has a consensus price target of $14.50, representing about 153.7% upside from its current price of $5.72.

  • Amount of Analyst Coverage

    Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bolt Biotherapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bolt Biotherapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bolt Biotherapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bolt Biotherapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.72% of the float of Bolt Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bolt Biotherapeutics has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bolt Biotherapeutics has recently increased by 200.82%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bolt Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Bolt Biotherapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Bolt Biotherapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Bolt Biotherapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $190,639.00 in company stock, which represents 1.7284% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Bolt Biotherapeutics insiders have bought 148.52% more of their company's stock than they have sold. Specifically, they have bought $319,000.00 in company stock and sold $128,361.00 in company stock.

  • Percentage Held by Insiders

    9.40% of the stock of Bolt Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bolt Biotherapeutics' insider trading history.
Receive BOLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BOLT Stock News Headlines

Microscopic footage reveals immune cells destroying cancer cells
Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.tc pixel
Bolt Biotherapeutics to Participate in Upcoming Conferences
See More Headlines

BOLT Stock Analysis - Frequently Asked Questions

Bolt Biotherapeutics' stock was trading at $5.47 at the start of the year. Since then, BOLT stock has increased by 4.5% and is now trading at $5.7150.

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($2.25) EPS for the quarter, beating analysts' consensus estimates of ($3.68) by $1.43. The company earned $450 thousand during the quarter, compared to the consensus estimate of $450 thousand. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 132.36% and a negative net margin of 611.47%.

Bolt Biotherapeutics shares reverse split on the morning of Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Bolt Biotherapeutics (BOLT) raised $213 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 11,500,000 shares at $18.00-$19.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include onsemi (ON), Enterprise Products Partners (EPD), NIO (NIO), Energy Transfer (ET), Achilles Therapeutics (ACHL), Aldeyra Therapeutics (ALDX) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/12/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BOLT
CIK
1641281
Fax
N/A
Employees
23
Year Founded
2015

Price Target and Rating

High Price Target
$22.00
Low Price Target
$7.00
Potential Upside/Downside
+150.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($14.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.38 million
Net Margins
-611.47%
Pretax Margin
-611.47%
Return on Equity
-132.36%
Return on Assets
-53.78%

Debt

Debt-to-Equity Ratio
1.47
Current Ratio
2.61
Quick Ratio
2.61

Sales & Book Value

Annual Sales
$4.70 million
Price / Sales
2.38
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.81 per share
Price / Book
0.42

Miscellaneous

Outstanding Shares
1,926,000
Free Float
1,745,000
Market Cap
$11.17 million
Optionable
Not Optionable
Beta
0.85

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:BOLT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners